The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications

Science Immunology

Volumn 1, Issue 3, 2016, Pages

  Spiotto, Michael ^a   Fu, Yang Xin ^b   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041734576     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aag1266     Document Type: Article

References (107)

1. H. B. Stone, L. J. Peters, L. Milas, Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl. Cancer Inst. 63, 1229–1235 (1979).
2. R. B. Cameron, P. J. Spiess, S. A. Rosenberg, Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J. Exp. Med. 171, 249–263 (1990).
3. D. E. Hallahan, D. R. Spriggs, M. A. Beckett, D. W. Kufe, R. R. Weichselbaum, Increased tumor necrosis factor a mRNA after cellular exposure to ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 86, 10104–10107 (1989).
4. B. C. Burnette, H. Liang, Y. Lee, L. Chlewicki, N. N. Khodarev, R. R. Weichselbaum, Y.-X. Fu, S. L. Auh, The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).
5. A. A. Lugade, E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, E. M. Lord, Radiation-induced IFN-g production within the tumor microenvironment influences antitumor immunity. J. Immunol. 180, 3132–3139 (2008).
6. B. Piret, S. Schoonbroodt, J. Piette, The ATM protein is required for sustained activation of NF-kB following DNA damage. Oncogene 18, 2261–2271 (1999).
7. M. A. Brach, R. Hass, M. L. Sherman, H. Gunji, R. Weichselbaum, D. Kufe, Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J. Clin. Invest. 88, 691–695 (1991).
8. A. A. Beg, D. Baltimore, An essential role for NF-kB in preventing TNF-a-induced cell death. Science 274, 782–784 (1996).
9. M. S. Diamond, M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, K. M. Murphy, R. D. Schreiber, Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
10. H. Ishikawa, Z. Ma, G. N. Barber, STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
11. B. Zhong, Y. Yang, S. Li, Y.-Y. Wang, Y. Li, F. Diao, C. Lei, X. He, L. Zhang, P. Tien, H.-B. Shu, The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29, 538–550 (2008).
12. L. Deng, H. Liang, M. Xu, X. Yang, B. Burnette, A. Arina, X.-D. Li, H. Mauceri, M. Beckett, T. Darga, X. Huang, T. F. Gajewski, Z. J. Chen, Y.-X. Fu, R. R. Weichselbaum, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).
13. D. R. E. Ranoa, A. D. Parekh, S. P. Pitroda, X. Huang, T. Darga, A. C. Wong, L. Huang, J. Andrade, J. P. Staley, T. Satoh, S. Akira, R. R. Weichselbaum, N. N. Khodarev, Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7, 26496–26515 (2016).
14. A. Ablasser, J. L. Schmid-Burgk, I. Hemmerling, G. L. Horvath, T. Schmidt, E. Latz, V. Hornung, Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503, 530–534 (2013).
15. N. N. Khodarev, A. J. Minn, E. V. Efimova, T. E. Darga, E. Labay, M. Beckett, H. J. Mauceri, B. Roizman, R. R. Weichselbaum, Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 67, 9214–9220 (2007).
16. H. Cheon, E. G. Holvey-Bates, J. W. Schoggins, S. Forster, P. Hertzog, N. Imanaka, C. M. Rice, M. W. Jackson, D. J. Junk, G. R. Stark, IFNb-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32, 2751–2763 (2013).
17. R. R. Weichselbaum, H. Ishwaran, T. Yoon, D. S. A. Nuyten, S. W. Baker, N. Khodarev, A. W. Su, A. Y. Shaikh, P. Roach, B. Kreike, B. Roizman, J. Bergh, Y. Pawitan, M. J. van de Vijver, A. J. Minn, An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 18490–18495 (2008).
18. M. Obeid, A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh, J.-L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Métivier, N. Larochette, P. van Endert, F. Ciccosanti, M. Piacentini, L. Zitvogel, G. Kroemer, Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
19. M. J. White, K. McArthur, D. Metcalf, R. M. Lane, J. C. Cambier, M. J. Herold, M. F. van Delft, S. Bedoui, G. Lessene, M. E. Ritchie, D. C. S. Huang, B. T. Kile, Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159, 1549–1562 (2014).
20. B. Sauter, M. L. Albert, L. Francisco, M. Larsson, S. Somersan, N. Bhardwaj, Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423–434 (2000).
21. M. T. Spiotto, P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y.-X. Fu, H. Schreiber, Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737–747 (2002).
22. B. Zhang, N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y.-X. Fu, R. R. Weichselbaum, D. A. Rowley, D. M. Kranz, H. Schreiber, Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49–55 (2007).
23. A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, E. M. Lord, Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516–7523 (2005).
24. + T cells: Changing strategies for cancer treatment. Blood 114, 589–595 (2009).
25. D. Schaue, J. A. Ratikan, K. S. Iwamoto, W. H. McBride, Maximizing tumor immunity with fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 83, 1306–1310 (2012).
26. A. B. Sharabi, C. J. Nirschl, C. M. Kochel, T. R. Nirschl, B. J. Francica, E. Velarde, T. L. Deweese, C. G. Drake, Stereotactic radiation therapy augments antigen-specific PD-1–mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. Res. 3, 345–355 (2015).
27. E. A. Reits, J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K. Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, A. Griekspoor, E. Mesman, F. A. Verreck, H. Spits, J. Schlom, P. van Veelen, J. J. Neefjes, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259–1271 (2006).
28. A. Sharma, B. Bode, R. H. Wenger, K. Lehmann, A. A. Sartori, H. Moch, A. Knuth, L. von Boehmer, M. van den Broek, g-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLOS One 6, e28217 (2011).
29. S. Morel, F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.-L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.-C. Cerottini, T. Boon, J. E. Gairin, B. J. Van den Eynde, Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107–117 (2000).
30. H. Yan, V. Kapoor, K. Nguyen, W. J. Akers, H. Li, J. Scott, R. Laforest, B. Rogers, D. Thotala, D. Hallahan, Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers. Oncotarget 10.18632/oncotarget.9713 (2016).
31. + T cells via dendritic cell activation. J. Immunol. 189, 558–566 (2012).
32. J. Huang, Q. J. Wang, S. Yang, Y. F. Li, M. El-Gamil, S. A. Rosenberg, P. F. Robbins, Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J. Immunother. 34, 327–335 (2011).
33. A. Battaglia, A. Buzzonetti, E. Martinelli, M. Fanelli, M. Petrillo, G. Ferrandina, G. Scambia, A. Fattorossi, Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 76, 1546–1553 (2010).
34. S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, S. Demaria, Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099–3107 (2008).
35. Y. Meng, E. V. Efimova, K. W. Hamzeh, T. E. Darga, H. J. Mauceri, Y.-X. Fu, S. J. Kron, R. R. Weichselbaum, Radiation-inducible immunotherapy for cancer: Senescent tumor cells as a cancer vaccine. Mol. Ther. 20, 1046–1055 (2012).
36. R. K. Shrimali, Z. Yu, M. R. Theoret, D. Chinnasamy, N. P. Restifo, S. A. Rosenberg, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171–6180 (2010).
37. R. Ganss, E. Ryschich, E. Klar, B. Arnold, G. J. Hämmerling, Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462–1470 (2002).
38. T. F. Gajewski, The next hurdle in cancer immunotherapy: Overcoming the non–T-cell–inflamed tumor microenvironment. Semin. Oncol. 42, 663–671 (2015).
39. H. Tang, Y. Wang, L. K. Chlewicki, Y. Zhang, J. Guo, W. Liang, J. Wang, X. Wang, Y.-X. Fu, Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285–296 (2016).
40. S. Wan, S. Pestka, R. G. Jubin, Y. L. Lyu, Y.-C. Tsai, L. F. Liu, Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLOS One 7, e32542 (2012).
41. M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom, J. W. Hodge, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64, 4328–4337 (2004).
42. C. T. Garnett, C. Palena, M. Chakraborty, K.-Y. Tsang, J. Schlom, J. W. Hodge, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64, 7985–7994 (2004).
43. M. T. Spiotto, D. A. Rowley, H. Schreiber, Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10, 294–298 (2004).
44. C.-Y. Wu, L.-H. Yang, H.-Y. Yang, J. Knoff, S. Peng, Y.-H. Lin, C. Wang, R. D. Alvarez, S. I. Pai, R. B. S. Roden, C.-F. Hung, T.-C. Wu, Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin. Cancer Res. 20, 644–657 (2014).
45. K. Kärre, H. G. Ljunggren, G. Piontek, R. Kiessling, Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678 (1986).
46. A. Cerwenka, J. L. Baron, L. L. Lanier, Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. U.S.A. 98, 11521–11526 (2001).
47. S. Gasser, S. Orsulic, E. J. Brown, D. H. Raulet, The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186–1190 (2005).
48. A. Soriani, A. Zingoni, C. Cerboni, M. L. Iannitto, M. R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M. T. Petrucci, A. Guarini, R. Foà, A. Santoni, ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113, 3503–3511 (2009).
49. J. H. Fine, P. Chen, A. Mesci, D. S. J. Allan, S. Gasser, D. H. Raulet, J. R. Carlyle, Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res. 70, 7102–7113 (2010).
50. R. Noy, J. W. Pollard, Tumor-associated macrophages: From mechanisms to therapy. Immunity 41, 49–61 (2014).
51. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623–637 (2014).
52. C. Steidl, T. Lee, S. P. Shah, P. Farinha, G. Han, T. Nayar, A. Delaney, S. J. Jones, J. Iqbal, D. D. Weisenburger, M. A. Bast, A. Rosenwald, H.-K. Muller-Hermelink, L. M. Rimsza, E. Campo, J. Delabie, R. M. Braziel, J. R. Cook, R. R. Tubbs, E. S. Jaffe, G. Lenz, J. M. Connors, L. M. Staudt, W. C. Chan, R. D. Gascoyne, Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med. 362, 875–885 (2010).
53. C. Medrek, F. Pontén, K. Jirström, K. Leandersson, The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306 (2012).
54. L. Milas, J. Wike, N. Hunter, J. Volpe, I. Basic, Macrophage content of murine sarcomas and carcinomas: Associations with tumor growth parameters and tumor radiocurability. Cancer Res. 47, 1069–1075 (1987).
55. C. Bergenfelz, A.-M. Larsson, K. von Stedingk, S. Gruvberger-Saal, K. Aaltonen, S. Jansson, H. Jernström, H. Janols, M. Wullt, A. Bredberg, L. Rydén, K. Leandersson, Systemic monocytic-MDSCs are generated from monocytes and correlate with disease progression in breast cancer patients. PLOS One 10, e0127028 (2015).
56. A. Filatenkov, J. Baker, A. M. S. Mueller, J. Kenkel, G.-O. Ahn, S. Dutt, N. Zhang, H. Kohrt, K. Jensen, S. Dejbakhsh-Jones, J. A. Shizuru, R. N. Negrin, E. G. Engleman, S. Strober, Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Cancer Res. 21, 3727–3739 (2015).
57. M. Kioi, H. Vogel, G. Schultz, R. M. Hoffman, G. R. Harsh, J. M. Brown, Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694–705 (2010).
58. S.-C. Wang, C.-F. Yu, J.-H. Hong, C.-S. Tsai, C.-S. Chiang, Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLOS One 8, e69182 (2013).
59. J. Xu, J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. McBride, L. Wu, CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782–2794 (2013).
60. G.-O. Ahn, D. Tseng, C.-H. Liao, M. J. Dorie, A. Czechowicz, J. M. Brown, Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. U.S.A. 107, 8363–8368 (2010).
61. G.-O. Ahn, J. M. Brown, Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193–205 (2008).
62. +/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602 (2013).
63. P. J. Coates, J. K. Rundle, S. A. Lorimore, E. G. Wright, Indirect macrophage responses to ionizing radiation: Implications for genotype-dependent bystander signaling. Cancer Res. 68, 450–456 (2008).
64. R. J. North, Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J. Exp. Med. 164, 1652–1666 (1986).
65. E. L. Kachikwu, K. S. Iwamoto, Y.-P. Liao, J. J. DeMarco, N. Agazaryan, J. S. Economou, W. H. McBride, D. Schaue, Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128–1135 (2011).
66. + regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. U.S.A. 110, 17945–17950 (2013).
67. O. S. Qureshi, Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. K. Walker, D. M. Sansom, Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
68. T. L. Walunas, D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, J. A. Bluestone, CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405–413 (1994).
69. S. Demaria, N. Kawashima, A. M. Yang, M. L. Devitt, J. S. Babb, J. P. Allison, S. C. Formenti, Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11 (2 Pt. 1), 728–734 (2005).
70. K. A. Pilones, N. Kawashima, A. M. Yang, J. S. Babb, S. C. Formenti, S. Demaria, Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin. Cancer Res. 15, 597–606 (2009).
71. M. G. Ruocco, K. A. Pilones, N. Kawashima, M. Cammer, J. Huang, J. S. Babb, M. Liu, S. C. Formenti, M. L. Dustin, S. Demaria, Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J. Clin. Invest. 122, 3718–3730 (2012).
72. L. Deng, H. Liang, B. Burnette, M. Beckett, T. Darga, R. R. Weichselbaum, Y.-X. Fu, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).
73. S. J. Dovedi, A. L. Adlard, G. Lipowska-Bhalla, C. McKenna, S. Jones, E. J. Cheadle, I. J. Stratford, E. Poon, M. Morrow, R. Stewart, H. Jones, R. W. Wilkinson, J. Honeychurch, T. M. Illidge, Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458–5468 (2014).
74. J. Zeng, A. P. See, J. Phallen, C. M. Jackson, Z. Belcaid, J. Ruzevick, N. Durham, C. Meyer, T. J. Harris, E. Albesiano, G. Pradilla, E. Ford, J. Wong, H.-J. Hammers, D. Mathios, B. Tyler, H. Brem, P. T. Tran, D. Pardoll, C. G. Drake, M. Lim, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343–349 (2013).
75. C. Twyman-Saint Victor, A. J. Rech, A. Maity, R. Rengan, K. E. Pauken, E. Stelekati, J. L. Benci, B. Xu, H. Dada, P. M. Odorizzi, R. S. Herati, K. D. Mansfield, D. Patsch, R. K. Amaravadi, L. M. Schuchter, H. Ishwaran, R. Mick, D. A. Pryma, X. Xu, M. D. Feldman, T. C. Gangadhar, S. M. Hahn, E. J. Wherry, R. H. Vonderheide, A. J. Minn, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
76. M. J. Gough, M. R. Crittenden, M. Sarff, P. Pang, S. K. Seung, J. T. Vetto, H.-M. Hu, W. L. Redmond, J. Holland, A. D. Weinberg, Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J. Immunother. 33, 798–809 (2010).
77. Z. Belcaid, J. A. Phallen, J. Zeng, A. P. See, D. Mathios, C. Gottschalk, S. Nicholas, M. Kellett, J. Ruzevick, C. Jackson, E. Albesiano, N. M. Durham, X. Ye, P. T. Tran, B. Tyler, J. W. Wong, H. Brem, D. M. Pardoll, C. G. Drake, M. Lim, Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLOS One 9, e101764 (2014).
78. S. Maleki Vareki, M. Rytelewski, R. Figueredo, D. Chen, P. J. Ferguson, M. Vincent, W. Min, X. Zheng, J. Koropatnick, Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 5, 2778–2791 (2014).
79. F. Bouquet, A. Pal, K. A. Pilones, S. Demaria, B. Hann, R. J. Akhurst, J. S. Babb, S. M. Lonning, J. K. DeWyngaert, S. C. Formenti, M. H. Barcellos-Hoff, TGFb1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 17, 6754–6765 (2011).
80. C. Vanpouille-Box, J. M. Diamond, K. A. Pilones, J. Zavadil, J. S. Babb, S. C. Formenti, M. H. Barcellos-Hoff, S. Demaria, TGFb is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232–2242 (2015).
81. L. Levy, I. Mishalian, R. Bayuch, L. Zolotarov, J. Michaeli, Z. G. Fridlender, Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology 4, e998469 (2015).
82. S. Ugel, E. Peranzoni, G. Desantis, M. Chioda, S. Walter, T. Weinschenk, J. C. Ochando, A. Cabrelle, S. Mandruzzato, V. Bronte, Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2, 628–639 (2012).
83. A. M. Aalbers, M. J. Aarts, A. D. G. Krol, C. A. M. Marijnen, E. F. M. Posthuma, The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia. Neth. J. Med. 74, 122–129 (2016).
84. C. M. Jackson, C. M. Kochel, C. J. Nirschl, N. M. Durham, J. Ruzevick, A. Alme, B. J. Francica, J. Elias, A. Daniels, T. W. Dubensky Jr., P. Lauer, D. G. Brockstedt, E. G. Baxi, P. A. Calabresi, J. M. Taube, C. A. Pardo, H. Brem, D. M. Pardoll, M. Lim, C. G. Drake, Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin. Cancer Res. 22, 1161–1172 (2016).
85. M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, N. Hacohen, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
86. E. Montecino-Rodriguez, B. Berent-Maoz, K. Dorshkind, Causes, consequences, and reversal of immune system aging. J. Clin. Invest. 123, 958–965 (2013).
87. K. Schreiber, A. Arina, B. Engels, M. T. Spiotto, J. Sidney, A. Sette, T. G. Karrison, R. R. Weichselbaum, D. A. Rowley, H. Schreiber, Spleen cells from young but not old immunized mice eradicate large established cancers. Clin. Cancer Res. 18, 2526–2533 (2012).
88. N. Iida, A. Dzutsev, C. A. Stewart, L. Smith, N. Bouladoux, R. A. Weingarten, D. A. Molina, R. Salcedo, T. Back, S. Cramer, R.-M. Dai, H. Kiu, M. Cardone, S. Naik, A. K. Patri, E. Wang, F. M. Marincola, K. M. Frank, Y. Belkaid, G. Trinchieri, R. S. Goldszmid, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
89. M. Vétizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. P. Roberti, C. P. M. Duong, V. Poirier-Colame, A. Roux, S. Becharef, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. P. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P.-L. Woerther, E. Chachaty, N. Chaput, C. Robert, C. Mateus, G. Kroemer, D. Raoult, I. G. Boneca, F. Carbonnel, M. Chamaillard, L. Zitvogel, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
90. S. Siva, M. P. MacManus, R. F. Martin, O. A. Martin, Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Lett. 356, 82–90 (2015).
91. J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K.-Y. Tsang, J. Yokokawa, J. W. Hodge, C. Ménard, K. Camphausen, C. N. Coleman, F. Sullivan, S. M. Steinberg, J. Schlom, W. Dahut, Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353–3362 (2005).
92. P. W. Kantoff, C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, Y. Xu, M. W. Frohlich, P. F. Schellhammer; IMPACT Study Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
93. J. D. Brody, W. Z. Ai, D. K. Czerwinski, J. A. Torchia, M. Levy, R. H. Advani, Y. H. Kim, R. T. Hoppe, S. J. Knox, L. K. Shin, I. Wapnir, R. J. Tibshirani, R. Levy, In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J. Clin. Oncol. 28, 4324–4332 (2010).
94. S. K. Seung, B. D. Curti, M. Crittenden, E. Walker, T. Coffey, J. C. Siebert, W. Miller, R. Payne, L. Glenn, A. Bageac, W. J. Urba, Phase 1 study of stereotactic body radiotherapy and interleukin-2—Tumor and immunological responses. Sci. Transl. Med. 4, 137ra74 (2012).
95. E. B. Golden, A. Chhabra, A. Chachoua, S. Adams, M. Donach, M. Fenton-Kerimian, K. Friedman, F. Ponzo, J. S. Babb, J. Goldberg, S. Demaria, S. C. Formenti, Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial. Lancet Oncol. 16, 795–803 (2015).
96. M. A. Postow, M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan, S. Kitano, Z. Mu, T. Rasalan, M. Adamow, E. Ritter, C. Sedrak, A. A. Jungbluth, R. Chua, A. S. Yang, R.-A. Roman, S. Rosner, B. Benson, J. P. Allison, A. M. Lesokhin, S. Gnjatic, J. D. Wolchok, Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
97. S. M. Hiniker, D. S. Chen, S. Reddy, D. T. Chang, J. C. Jones, J. A. Mollick, S. M. Swetter, S. J. Knox, A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5, 404–407 (2012).
98. E. B. Golden, S. Demaria, P. B. Schiff, A. Chachoua, S. C. Formenti, An abscopal response to radiation and ipilimumab in a patient with metastatic non–small cell lung cancer. Cancer Immunol. Res. 1, 365–372 (2013).
99. E. D. Kwon, C. G. Drake, H. I. Scher, K. Fizazi, A. Bossi, A. J. M. van den Eertwegh, M. Krainer, N. Houede, R. Santos, H. Mahammedi, S. Ng, M. Maio, F. A. Franke, S. Sundar, N. Agarwal, A. M. Bergman, T. E. Ciuleanu, E. Korbenfeld, L. Sengeløv, S. Hansen, C. Logothetis, T. M. Beer, M. B. McHenry, P. Gagnier, D. Liu, W. R. Gerritsen; CA184-043 Investigators, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
100. C. Robert, J. Schachter, G. V. Long, A. Arance, J. J. Grob, L. Mortier, A. Daud, M. S. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. U. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, H. Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas; KEYNOTE-006 Investigators, Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
101. M. A. Postow, M. K. Callahan, J. D. Wolchok, Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
102. A. W. Silk, M. F. Bassetti, B. T. West, C. I. Tsien, C. D. Lao, Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2, 899–906 (2013).
103. C. D. Surh, J. Sprent, Homeostatic T cell proliferation: How far can T cells be activated to self-ligands? J. Exp. Med. 192, F9–F14 (2000).
104. + T cells. J. Exp. Med. 202, 907–912 (2005).
105. M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White, S. A. Rosenberg, Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233–5239 (2008).
106. A. V. Krauze, S. D. Myrehaug, M. G. Chang, D. J. Holdford, S. Smith, J. Shih, P. J. Tofilon, H. A. Fine, K. Camphausen, A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 92, 986–992 (2015).
107. J. L. Pugh, A. S. Sukhina, T. M. Seed, N. R. Manley, G. D. Sempowski, M. R. M. van den Brink, M. J. Smithey, J. Nikolich-Žugich, Histone deacetylation critically determines T cell subset radiosensitivity. J. Immunol. 193, 1451–1458 (2014).